Virbac posted sales of 345.7 million euros for the first quarter of 2024, up 9.8% (+9.7% excluding acquisitions and at constant exchange rates), driven by more sustained momentum in the animal health market.

This increase benefited firstly from a contribution from volumes estimated at around 6.4 growth points, and then, to a lesser extent, from a more modest price effect due in particular to the slowdown in inflation.

For 2024 as a whole, at constant exchange rates and scope of consolidation, Virbac forecasts sales growth estimated, at this stage, at between 4 and 6%, and an adjusted EBIT/sales ratio of around 15%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.